Global Whole Genome Bisulfite Sequencing (WGBS) Market, By Product and Service (DNA Extraction, DNA Fragmentation, DNA Repair, Adapter Ligation, Bisulfite Treatment, PCR Amplification), Application (Stem Cell Applications, Developmental Biology, Early Diagnosis of Diseases, Forensic Science), End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutes, Contract Research Organizations) – Industry Trends and Forecast to 2029.
Whole Genome Bisulfite Sequencing (WGBS) Market Analysis and Size
Whole genome bisulfite sequencing is a next-generation sequencing technology that uses sodium bisulfite to determine the methylation status of single cytosines prior to high-throughput DNA sequencing. The status of DNA methylation at various genes can reveal information about gene regulation and transcriptional activities.
Data Bridge Market Research analyses that the whole genome bisulfite sequencing (WGBS) market which is expected to grow at a healthy CAGR during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Whole Genome Bisulfite Sequencing (WGBS) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product and Service (DNA Extraction, DNA Fragmentation, DNA Repair, Adapter Ligation, Bisulfite Treatment, PCR Amplification), Application (Stem Cell Applications, Developmental Biology, Early Diagnosis of Diseases, Forensic Science), End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutes, Contract Research Organizations) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Illumina, Inc. (U.S.), Epigentek Group Inc (U.S.), CD Genomics (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Novogene Co., Ltd. (China), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), BGI (China), Nebula Genomics (U.S.), Agilent Technologies (U.S.), Qiagen (Germany), Macrogen Inc. (South korea), Oxford Nanopore Technologies plc. (U.K.), Veritas (U.S.) |
|
Market Opportunities |
|
Market Definition
Whole genome bisulfite sequencing (WGBS) is a critical technique in methylome research. Although a number of tools have been developed to address the mapping challenges caused by bisulfite treatment, the most recent tools available have not been evaluated in terms of read mapping performance as well as biological insights in multiple mammals.
Global Whole Genome Bisulfite Sequencing (WGBS) Market Dynamics
Drivers
- Rise in genome sequencing
Genome sequencing enables genome-wide methylation profiling at the single-base level which provides methylation status of every CpG locus including partial methylation domains, gene deserts, remote regulatory elements, others which reveals methylation sequence background and reveals absolute DNA methylation levels. During the forecast period of 2022–2029, these factors are boosting the growth of the whole genome bisulfite sequencing (WGBS) market.
- Rising applications of whole genome sequencing
Single nucleotide resolution methylation profiling at CG, CHG, and CHH sites. differentially methylated sites linked to experimental treatments or sample conditions, understanding cell differentiation or tissue development mechanisms using methylation profiles and early disease and cancer detection by detecting DNA hypermethylation or hypomethylation. These all are the applications of whole genome sequencing which boost the growth of the market.
Opportunities
- Rising advanced techniques
The increasing number of research and development activities, as well as the adoption of advanced techniques. For instance, whole genome bisulfite sequencing (WGBS) detects methylated cytosines by pre-sequencing the DNA with sodium bisulfite. WGBS has established itself as the gold standard for studying genome-wide methylation at single base resolution. These will provide various opportunities for the growth of the whole genome bisulfite sequencing (WGBS) market during the forecast period.
Restraints/Challenges
- Low coverage of whole genome bisulfite sequencing
The use of whole genome bisulfite sequencing has been hampered primarily by its high cost, complex data output, and low required coverage. Many studies using whole genome bisulfite sequencing assays have few or no biological replicates due to the high amount and subsequent cost of DNA input. Bisulfite converts unmethylated cytosines to thymidines, reducing sequence complexity, which can make it difficult to create alignments.
This whole genome bisulfite sequencing (WGBS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the whole genome bisulfite sequencing (WGBS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Whole Genome Bisulfite Sequencing (WGBS) Market Scope
The whole genome bisulfite sequencing (WGBS) market is segmented on the basis of product and services, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Service
- DNA Extraction
- DNA Fragmentation
- DNA Repair
- Adapter Ligation
- Bisulfite Treatment
- PCR Amplification
Application
- Stem Cell Applications
- Developmental Biology
- Early Diagnosis of Diseases
- Forensic Science
End User
- Pharmaceutical and Biotechnology Companies
- Academic and Government Institutes
- Contract Research Organizations
Whole Genome Bisulfite Sequencing (WGBS) Market Regional Analysis/Insights
The whole genome bisulfite sequencing (WGBS) market is analysed and market size insights and trends are provided by country, product and services, application and end user as referenced above.
The countries covered in the whole genome bisulfite sequencing (WGBS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the whole genome bisulfite sequencing (WGBS) market due to the surging levels of investment for the development of the healthcare industry along with growth of new technologies.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the increasing number of population suffering from diabetes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Whole Genome Bisulfite Sequencing (WGBS) Market Share Analysis
The whole genome bisulfite sequencing (WGBS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to whole genome bisulfite sequencing (WGBS) market.
Some of the major players operating in the whole genome bisulfite sequencing (WGBS) market are:
- Illumina, Inc. (U.S.)
- Epigentek Group Inc (U.S.)
- CD Genomics (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Novogene Co., Ltd. (China)
- PerkinElmer, Inc. (U.S.)
- Promega Corporation (U.S.)
- BGI (China)
- Nebula Genomics (U.S.)
- Agilent Technologies (U.S.)
- Qiagen (Germany)
- Macrogen Inc. (South korea)
- Oxford Nanopore Technologies plc. (U.K.)
- Veritas (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 COST ANALYSIS BREAKDOWN
8 TECHNONLOGY ROADMAP
9 INNOVATION TRACKER AND STRATEGIC ANALYSIS
9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
9.1.1 JOINT VENTURES
9.1.2 MERGERS AND ACQUISITIONS
9.1.3 LICENSING AND PARTNERSHIP
9.1.4 TECHNOLOGY COLLABORATIONS
9.1.5 STRATEGIC DIVESTMENTS
9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
9.3 STAGE OF DEVELOPMENT
9.4 TIMELINES AND MILESTONES
9.5 INNOVATION STRATEGIES AND METHODOLOGIES
9.6 RISK ASSESSMENT AND MITIGATION
9.7 FUTURE OUTLOOK
10 REGULATORY COMPLIANCE
10.1 REGULATORY AUTHORITIES
10.2 REGULATORY CLASSIFICATIONS
10.2.1 CLASS I
10.2.2 CLASS II
10.2.3 CLASS III
10.3 REGULATORY SUBMISSIONS
10.4 INTERNATIONAL HARMONIZATION
10.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
10.6 REGULATORY CHALLENGES AND STRATEGIES
11 REIMBURSEMENT FRAMEWORK
12 VALUE CHAIN ANALYSIS
13 HEALTHCARE ECONOMY
13.1 HEALTHCARE EXPENDITURE
13.2 CAPITAL EXPENDITURE
13.3 CAPEX TRENDS
13.4 CAPEX ALLOCATION
13.5 FUNDING SOURCES
13.6 INDUSTRY BENCHMARKS
13.7 GDP RATION IN OVERALL GDP
13.8 HEALTHCARE SYSTEM STRUCTURE
13.9 GOVERNMENT POLICIES
13.1 ECONOMIC DEVELOPMENT
14 GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET, BY PRODUCT AND SERVICES
14.1 OVERVIEW
14.2 PRODUCT
14.2.1 INSTRUMENTS
14.2.1.1. BY MODALITY
14.2.1.1.1. BENCHTOP
14.2.1.1.1.1 ASP (IN USD)
14.2.1.1.1.2 MARKET VOLUME (IN UNITS)
14.2.1.1.1.3 MARKET VALUE (IN USD)
14.2.1.1.2. STANDALONE
14.2.1.1.2.1 ASP (IN USD)
14.2.1.1.2.2 MARKET VOLUME (IN UNITS)
14.2.1.1.2.3 MARKET VALUE (IN USD)
14.2.1.1.3. PORTABLE
14.2.1.1.3.1 ASP (IN USD)
14.2.1.1.3.2 MARKET VOLUME (IN UNITS)
14.2.1.1.3.3 MARKET VALUE (IN USD)
14.2.1.2. BY MODE
14.2.1.2.1. AUTOMATIC
14.2.1.2.1.1 ASP (IN USD)
14.2.1.2.1.2 MARKET VOLUME (IN UNITS)
14.2.1.2.1.3 MARKET VALUE (IN USD)
14.2.1.2.2. MANUAL
14.2.1.2.2.1 ASP (IN USD)
14.2.1.2.2.2 MARKET VOLUME (IN UNITS)
14.2.1.2.2.3 MARKET VALUE (IN USD)
14.2.1.3. BY TYPE
14.2.1.3.1. PCR INSTRUMENTS
14.2.1.3.1.1 QPCR INSTRUMENTS
14.2.1.3.1.1.1. ASP (IN USD)
14.2.1.3.1.1.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.1.3. MARKET VALUE (IN USD)
14.2.1.3.1.2 REVERSE TRANSCRIPTASE (RT-PCR)
14.2.1.3.1.2.1. ASP (IN USD)
14.2.1.3.1.2.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.2.3. MARKET VALUE (IN USD)
14.2.1.3.1.3 MULTIPLEX PCR
14.2.1.3.1.3.1. ASP (IN USD)
14.2.1.3.1.3.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.3.3. MARKET VALUE (IN USD)
14.2.1.3.1.4 NESTED PCR
14.2.1.3.1.4.1. ASP (IN USD)
14.2.1.3.1.4.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.4.3. MARKET VALUE (IN USD)
14.2.1.3.1.5 LONG-RANGE PCR
14.2.1.3.1.5.1. ASP (IN USD)
14.2.1.3.1.5.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.5.3. MARKET VALUE (IN USD)
14.2.1.3.1.6 SINGLE CELL PCR
14.2.1.3.1.6.1. ASP (IN USD)
14.2.1.3.1.6.2. MARKET VOLUME (IN UNITS)
14.2.1.3.1.6.3. MARKET VALUE (IN USD)
14.2.1.3.1.7 OTHERS
14.2.1.3.2. MICROCENTRIFUGE
14.2.1.3.2.1 ASP (IN USD)
14.2.1.3.2.2 MARKET VOLUME (IN UNITS)
14.2.1.3.2.3 MARKET VALUE (IN USD)
14.2.1.3.3. TRANSILLUMINATOR
14.2.1.3.3.1 ASP (IN USD)
14.2.1.3.3.2 MARKET VOLUME (IN UNITS)
14.2.1.3.3.3 MARKET VALUE (IN USD)
14.2.1.3.4. ELECTROPHORESIS UNIT
14.2.1.3.4.1 ASP (IN USD)
14.2.1.3.4.2 MARKET VOLUME (IN UNITS)
14.2.1.3.4.3 MARKET VALUE (IN USD)
14.2.1.3.5. GEL TRAYS AND TANK
14.2.1.3.5.1 ASP (IN USD)
14.2.1.3.5.2 MARKET VOLUME (IN UNITS)
14.2.1.3.5.3 MARKET VALUE (IN USD)
14.2.1.3.6. OTHERS
14.2.2 CONSUMABLES
14.2.2.1. KITS
14.2.2.1.1. BISULFITE KIT
14.2.2.1.2. DNA PURIFICATION KIT
14.2.2.1.2.1 ASP (IN USD)
14.2.2.1.2.2 MARKET VOLUME (IN UNITS)
14.2.2.1.2.3 MARKET VALUE (IN USD)
14.2.2.1.3. BISULFITE TREATMENT OF GENOMIC DNA
14.2.2.1.3.1 ASP (IN USD)
14.2.2.1.3.2 MARKET VOLUME (IN UNITS)
14.2.2.1.3.3 MARKET VALUE (IN USD)
14.2.2.1.4. SAMPLE PREPARATION KIT
14.2.2.1.4.1 ASP (IN USD)
14.2.2.1.4.2 MARKET VOLUME (IN UNITS)
14.2.2.1.4.3 MARKET VALUE (IN USD)
14.2.2.1.5. DNA EXTRACTION KIT
14.2.2.1.5.1 ASP (IN USD)
14.2.2.1.5.2 MARKET VOLUME (IN UNITS)
14.2.2.1.5.3 MARKET VALUE (IN USD)
14.2.2.1.5.4
14.2.2.1.6. DNA REPAIR KIT
14.2.2.1.6.1 ASP (IN USD)
14.2.2.1.6.2 MARKET VOLUME (IN UNITS)
14.2.2.1.6.3 MARKET VALUE (IN USD)
14.2.2.1.7. OTHERS
14.2.2.2. BUFFER
14.2.2.2.1. ASP (IN USD)
14.2.2.2.2. MARKET VOLUME (IN UNITS)
14.2.2.2.3. MARKET VALUE (IN USD)
14.2.2.3. GELS
14.2.2.3.1. ASP (IN USD)
14.2.2.3.2. MARKET VOLUME (IN UNITS)
14.2.2.3.3. MARKET VALUE (IN USD)
14.2.2.4. TUBES
14.2.2.4.1. ASP (IN USD)
14.2.2.4.2. MARKET VOLUME (IN UNITS)
14.2.2.4.3. MARKET VALUE (IN USD)
14.2.2.5. DYES
14.2.2.5.1. ASP (IN USD)
14.2.2.5.2. MARKET VOLUME (IN UNITS)
14.2.2.5.3. MARKET VALUE (IN USD)
14.2.2.6. OTHERS
14.3 SERVICES
14.3.1 BISULFITE TREATMENT/ CONVERSION
14.3.1.1. ASP (IN USD)
14.3.1.2. MARKET VOLUME (NUMBER OF TEST)
14.3.1.3. MARKET VALUE (IN USD)
14.3.2 DATA ANALYSIS/BIOINFORMATICS
14.3.2.1. DATA MINING
14.3.2.1.1. ASP (IN USD)
14.3.2.1.2. MARKET VOLUME (NUMBER OF TEST)
14.3.2.1.3. MARKET VALUE (IN USD)
14.3.2.2. STANDARD
14.3.2.2.1. ASP (IN USD)
14.3.2.2.2. MARKET VOLUME (NUMBER OF TEST)
14.3.2.2.3. MARKET VALUE (IN USD)
14.3.2.3. DIFFERENTIAL METHYLATION ANALYSIS
14.3.2.3.1. ASP (IN USD)
14.3.2.3.2. MARKET VOLUME (NUMBER OF TEST)
14.3.2.3.3. MARKET VALUE (IN USD)
14.3.2.4. GENE ONTOLOGY TERMS ANALYSIS
14.3.2.4.1. ASP (IN USD)
14.3.2.4.2. MARKET VOLUME (NUMBER OF TEST)
14.3.2.4.3. MARKET VALUE (IN USD)
14.3.2.5. OTHERS
14.3.3 SEQUENCING & LIBRARY PREPARATION
14.3.3.1. ASP (IN USD)
14.3.3.2. MARKET VOLUME (NUMBER OF TEST)
14.3.3.3. MARKET VALUE (IN USD)
14.3.4 CUSTOM SERVICES
14.3.4.1. ASP (IN USD)
14.3.4.2. MARKET VOLUME (NUMBER OF TEST)
14.3.4.3. MARKET VALUE (IN USD)
14.3.5 OTHERS
15 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY APPLICATION
15.1 OVERVIEW
15.2 STEM CELL APPLICATIONS
15.2.1 PRODUCT
15.2.1.1. INSTRUMENTS
15.2.1.2. CONSUMBALES
15.2.2 SERVICES
15.3 EMBRYONIC DEVELOPMENT
15.3.1 PRODUCT
15.3.1.1. INSTRUMENTS
15.3.1.2. CONSUMBALES
15.3.2 SERVICES
15.4 FORENSIC SCIENCE
15.4.1 PRODUCT
15.4.1.1. INSTRUMENTS
15.4.1.2. CONSUMBALES
15.4.2 SERVICES
15.5 EARLY DIAGNOSIS OF DISEASES
15.5.1 CANCER
15.5.1.1. BREAST CANCER
15.5.1.1.1. PRODUCT
15.5.1.1.1.1 INSTRUMENTS
15.5.1.1.1.2 CONSUMBALES
15.5.1.1.2. SERVICES
15.5.1.2. BLADDER CANCER
15.5.1.2.1. PRODUCT
15.5.1.2.1.1 INSTRUMENTS
15.5.1.2.1.2 CONSUMBALES
15.5.1.2.2. SERVICES
15.5.1.3. LYMPH CANCER
15.5.1.3.1. PRODUCT
15.5.1.3.1.1 INSTRUMENTS
15.5.1.3.1.2 CONSUMBALES
15.5.1.3.2. SERVICES
15.5.1.4. LIVER CANCER
15.5.1.4.1. PRODUCT
15.5.1.4.1.1 INSTRUMENTS
15.5.1.4.1.2 CONSUMBALES
15.5.1.4.2. SERVICES
15.5.1.5. OTHERS
15.5.2 COMPLEX DISEASES
15.5.2.1. AUTOIMMUNE
15.5.2.1.1. PRODUCT
15.5.2.1.1.1 INSTRUMENTS
15.5.2.1.1.2 CONSUMBALES
15.5.2.1.2. SERVICES
15.5.2.2. CARDIOVASCULAR
15.5.2.2.1. PRODUCT
15.5.2.2.1.1 INSTRUMENTS
15.5.2.2.1.2 CONSUMBALES
15.5.2.2.2. SERVICES
15.5.2.3. MENTAL DISORDER
15.5.2.3.1. PRODUCT
15.5.2.3.1.1 INSTRUMENTS
15.5.2.3.1.2 CONSUMBALES
15.5.2.3.2. SERVICES
15.5.2.4. GENETIC DISEASE
15.5.2.4.1. PRODUCT
15.5.2.4.1.1 INSTRUMENTS
15.5.2.4.1.2 CONSUMBALES
15.5.2.4.2. SERVICES
15.5.3 OTHERS
16 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY WORKFLOW
16.1 OVERVIEW
16.2 LIBRARY PREPARATION
16.3 SEQUENCING
16.4 BIOINFORMATIC ANALYSIS
16.5 OTHERS
17 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY END USER
17.1 OVERVIEW
17.2 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS AND CONTRACT RESEARCH ORGANIZATIONS (CDMOS & CROS)
17.2.1 BY TYPE
17.2.1.1. SMALL ENTERPRIZES
17.2.1.2. LARGE ENTERPRIZES
17.2.1.3. MEDIUM ENTERPRIZES
17.2.2 BY PRODUCT AND SERVICES
17.2.2.1. PRODUCT
17.2.2.1.1. INSTRUMENTS
17.2.2.1.2. CONSUMBALES
17.2.2.2. SERVICES
17.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
17.3.1 BY TYPE
17.3.1.1. SMALL ENTERPRIZES
17.3.1.2. LARGE ENTERPRIZES
17.3.1.3. MEDIUM ENTERPRIZES
17.3.2 BY PRODUCT AND SERVICES
17.3.2.1. PRODUCT
17.3.2.1.1. INSTRUMENTS
17.3.2.1.2. CONSUMBALES
17.3.2.2. SERVICES
17.4 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
17.4.1 BY PRODUCT AND SERVICES
17.4.1.1. PRODUCT
17.4.1.1.1. INSTRUMENTS
17.4.1.1.2. CONSUMBALES
17.4.1.2. SERVICES
17.5 OTHERS
18 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 DIRECT TENDER
18.3 RETAIL SALES
18.3.1 OFFLINE
18.3.2 ONLINES
18.4 OTHERS
19 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY GEOGRAPHY
19.1 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1.1 NORTH AMERICA
19.1.1.1. U.S.
19.1.1.2. CANADA
19.1.1.3. MEXICO
19.1.2 EUROPE
19.1.2.1. GERMANY
19.1.2.2. FRANCE
19.1.2.3. U.K.
19.1.2.4. HUNGARY
19.1.2.5. LITHUANIA
19.1.2.6. AUSTRIA
19.1.2.7. IRELAND
19.1.2.8. NORWAY
19.1.2.9. POLAND
19.1.2.10. ITALY
19.1.2.11. SPAIN
19.1.2.12. RUSSIA
19.1.2.13. TURKEY
19.1.2.14. BELGIUM
19.1.2.15. NETHERLANDS
19.1.2.16. SWITZERLAND
19.1.2.17. REST OF EUROPE
19.1.3 ASIA-PACIFIC
19.1.3.1. JAPAN
19.1.3.2. CHINA
19.1.3.3. SOUTH KOREA
19.1.3.4. INDIA
19.1.3.5. AUSTRALIA
19.1.3.6. SINGAPORE
19.1.3.7. THAILAND
19.1.3.8. MALAYSIA
19.1.3.9. INDONESIA
19.1.3.10. PHILIPPINES
19.1.3.11. VIETNAM
19.1.3.12. REST OF ASIA-PACIFIC
19.1.4 SOUTH AMERICA
19.1.4.1. BRAZIL
19.1.4.2. ARGENTINA
19.1.4.3. PERU
19.1.4.4. REST OF SOUTH AMERICA
19.1.5 MIDDLE EAST AND AFRICA
19.1.5.1. SOUTH AFRICA
19.1.5.2. SAUDI ARABIA
19.1.5.3. UAE
19.1.5.4. EGYPT
19.1.5.5. KUWAIT
19.1.5.6. ISRAEL
19.1.5.7. REST OF MIDDLE EAST AND AFRICA
20 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20.5 MERGERS & ACQUISITIONS
20.6 NEW PRODUCT DEVELOPMENT & APPROVALS
20.7 EXPANSIONS
20.8 REGULATORY CHANGES
20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
21 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, COMPANY PROFILE
22.1 ILLUMINA INC.
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPEMENTS
22.2 BERRY GENOMICS CO., LTD.
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPEMENTS
22.3 THERMO FISHER SCIENTIFIC, INC.
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPEMENTS
22.4 ZYMO RESEARCH CORPORATION.
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPEMENTS
22.5 QIAGEN
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPEMENTS
22.6 MERCK MILLIPORE
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPEMENTS
22.7 BIO-RAD LABORATORIES, INC.
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPEMENTS
22.8 F. HOFFMANN-LA ROCHE LTD.
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 NEW ENGLAND BIOLABS
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPEMENTS
22.1 AGILENT TECHNOLOGIES, INC.
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPEMENTS
22.11 PERKINELMER, INC.
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPEMENTS
22.12 MGI TECH CO., LTD.
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPEMENTS
22.13 LUCIGEN CORPORATION
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPEMENTS
22.14 NOVOGENE CO., LTD.
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPEMENTS
22.15 OMEGA BIO-TEK, INC.
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPEMENTS
22.16 SEEGENE INC.
22.16.1 COMPANY OVERVIEW
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPEMENTS
22.17 BIOMÉRIEUX S.A.
22.17.1 COMPANY OVERVIEW
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPEMENTS
22.18 ABBOTT LABOROTORIES
22.18.1 COMPANY OVERVIEW
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPEMENTS
22.19 FLUIDIGM CORPORATION
22.19.1 COMPANY OVERVIEW
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPEMENTS
22.2 DANAHER
22.20.1 COMPANY OVERVIEW
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPEMENTS
22.21 BECTON DICKINSON AND COMPANY
22.21.1 COMPANY OVERVIEW
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPEMENTS
22.22 TAKARA BIO, INC.
22.22.1 COMPANY OVERVIEW
22.22.2 REVENUE ANALYSIS
22.22.3 GEOGRAPHIC PRESENCE
22.22.4 PRODUCT PORTFOLIO
22.22.5 RECENT DEVELOPEMENTS
22.23 DIAGENODE DIAGNOSTICS
22.23.1 COMPANY OVERVIEW
22.23.2 REVENUE ANALYSIS
22.23.3 GEOGRAPHIC PRESENCE
22.23.4 PRODUCT PORTFOLIO
22.23.5 RECENT DEVELOPEMENTS
22.24 DIATECH PHARMACOGENETICS S.R.L.,
22.24.1 COMPANY OVERVIEW
22.24.2 REVENUE ANALYSIS
22.24.3 GEOGRAPHIC PRESENCE
22.24.4 PRODUCT PORTFOLIO
22.24.5 RECENT DEVELOPEMENTS
22.25 ABCAM PLC
22.25.1 COMPANY OVERVIEW
22.25.2 REVENUE ANALYSIS
22.25.3 GEOGRAPHIC PRESENCE
22.25.4 PRODUCT PORTFOLIO
22.25.5 RECENT DEVELOPEMENTS
22.26 ACTIVE MOTIF,INC
22.26.1 COMPANY OVERVIEW
22.26.2 REVENUE ANALYSIS
22.26.3 GEOGRAPHIC PRESENCE
22.26.4 PRODUCT PORTFOLIO
22.26.5 RECENT DEVELOPEMENTS
22.27 SBS GENETECH
22.27.1 COMPANY OVERVIEW
22.27.2 REVENUE ANALYSIS
22.27.3 GEOGRAPHIC PRESENCE
22.27.4 PRODUCT PORTFOLIO
22.27.5 RECENT DEVELOPEMENTS
22.28 EPPENDORF
22.28.1 COMPANY OVERVIEW
22.28.2 REVENUE ANALYSIS
22.28.3 GEOGRAPHIC PRESENCE
22.28.4 PRODUCT PORTFOLIO
22.28.5 RECENT DEVELOPEMENTS
22.29 ANALYTIK JENA
22.29.1 COMPANY OVERVIEW
22.29.2 REVENUE ANALYSIS
22.29.3 GEOGRAPHIC PRESENCE
22.29.4 PRODUCT PORTFOLIO
22.29.5 RECENT DEVELOPEMENTS
22.3 EUROFINS GENOMICS
22.31 BGI
22.31.1 COMPANY OVERVIEW
22.31.2 REVENUE ANALYSIS
22.31.3 GEOGRAPHIC PRESENCE
22.31.4 PRODUCT PORTFOLIO
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
